Table 2 A-C All statistically significant ARGs that are enriched after oral treatment with Ampicillin (A), Ciprofloxacin (B), or Fosfomycin (C)
ARG | Increase/Decrease | ||
|---|---|---|---|
24 h | 48 h | 72 h | |
A. Ampicillin | |||
 efrB | – | + | – |
 LlmA 23S ribosomal RNA methyltransferase | – | + | – |
 macB | – | – | + |
 mupA | – | + | – |
 mupB | – | + | – |
 patB | – | + | – |
 Streptomyces rishiriensis parY mutant conferring resistance to aminocoumarin | – | + | – |
 tetB(46) | – | + | – |
 tetB(60) | + | + | – |
B. Ciprofloxacin | |||
 ANT(6)-Ib | + | – | – |
 arlR | + | – | + |
 Bifidobacterium adolescentis rpoB conferring resistance to rifampicin | + | + | – |
 cepA beta-lactamase | + | – | + |
 cmeB | + | – | – |
 efrA | + | – | – |
 efrB | + | – | + |
 lsaB | – | + | – |
 macB | + | – | – |
 mupA | – | + | + |
 Nocardia rifampin resistant beta-subunit of RNA polymerase (rpoB2) | + | + | + |
 Streptomyces rishiriensis parY mutant conferring resistance to aminocoumarin | + | – | – |
 TaeA | – | + | – |
 tet(W/N/W) | + | – | – |
 tetA(60) | + | – | + |
 tetB(P) | + | – | – |
 tetM | + | – | – |
 tetW | + | – | – |
 ugd | + | – | – |
 vanRC | + | – | + |
 vanRG | – | + | – |
 vanRI | – | + | – |
 vanSC | + | – | – |
 vanWG | + | – | – |
 vanYG1 | – | + | – |
C. Fosfomycin | |||
 ANT(6)-Ib | + | – | + |
 Bifidobacteria intrinsic ileS conferring resistance to mupirocin | – | + | – |
 catB10 | + | – | – |
 cepA beta-lactamase | + | + | + |
 cmeB | + | + | + |
 macB | + | – | – |
 msbA | + | + | + |
 mupB | + | + | + |
 Nocardia rifampin resistant beta-subunit of RNA polymerase (rpoB2) | + | + | – |
 TaeA | + | + | – |
 tet37 | + | + | + |
 ugd | + | + | + |